ProKidney Corp. PROK

PROK Company Overview

ProKidney Corp. is a clinical-stage biotechnology company focused on developing cell therapy treatments for chronic kidney disease (CKD), particularly kidney disease associated with type 2 diabetes. The company operates within the regenerative medicine, biotechnology, and nephrology therapeutics sectors. Its primary product candidate is rilparencel, an autologous cellular therapy designed to preserve kidney function and delay or prevent progression to dialysis or kidney transplantation in patients with advanced CKD.

The company’s business model is centered on clinical development, regulatory advancement, and eventual commercialization of renal cell therapies. ProKidney has positioned itself within a large unmet medical need market, as CKD affects millions globally and existing therapies primarily slow disease progression rather than restore kidney function. The company traces its origins to research into autologous renal cell technologies and later became publicly traded through a business combination with a special purpose acquisition company (SPAC) in 2022. Public filings and company disclosures identify regenerative nephrology as the core strategic focus of the business.